1. Home
  2. BEAM vs SDRL Comparison

BEAM vs SDRL Comparison

Compare BEAM & SDRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • SDRL
  • Stock Information
  • Founded
  • BEAM 2017
  • SDRL 2005
  • Country
  • BEAM United States
  • SDRL Bermuda
  • Employees
  • BEAM N/A
  • SDRL N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • SDRL Oil & Gas Production
  • Sector
  • BEAM Health Care
  • SDRL Energy
  • Exchange
  • BEAM Nasdaq
  • SDRL Nasdaq
  • Market Cap
  • BEAM 2.3B
  • SDRL 1.9B
  • IPO Year
  • BEAM 2020
  • SDRL N/A
  • Fundamental
  • Price
  • BEAM $25.14
  • SDRL $30.33
  • Analyst Decision
  • BEAM Strong Buy
  • SDRL Strong Buy
  • Analyst Count
  • BEAM 12
  • SDRL 4
  • Target Price
  • BEAM $48.09
  • SDRL $51.00
  • AVG Volume (30 Days)
  • BEAM 2.3M
  • SDRL 716.3K
  • Earning Date
  • BEAM 11-04-2025
  • SDRL 11-05-2025
  • Dividend Yield
  • BEAM N/A
  • SDRL N/A
  • EPS Growth
  • BEAM N/A
  • SDRL N/A
  • EPS
  • BEAM N/A
  • SDRL 0.55
  • Revenue
  • BEAM $55,701,000.00
  • SDRL $1,307,000,000.00
  • Revenue This Year
  • BEAM N/A
  • SDRL $5.63
  • Revenue Next Year
  • BEAM $19.01
  • SDRL N/A
  • P/E Ratio
  • BEAM N/A
  • SDRL $54.36
  • Revenue Growth
  • BEAM N/A
  • SDRL N/A
  • 52 Week Low
  • BEAM $13.53
  • SDRL $17.74
  • 52 Week High
  • BEAM $35.25
  • SDRL $41.25
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 58.18
  • SDRL 49.34
  • Support Level
  • BEAM $20.23
  • SDRL $28.91
  • Resistance Level
  • BEAM $22.72
  • SDRL $30.54
  • Average True Range (ATR)
  • BEAM 1.68
  • SDRL 1.54
  • MACD
  • BEAM 0.36
  • SDRL 0.01
  • Stochastic Oscillator
  • BEAM 97.41
  • SDRL 53.40

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About SDRL Seadrill Limited

Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.

Share on Social Networks: